



1. An antibody-drug conjugate, being of Formula (XXX):






wherein d_{13} is 2; and the antibody comprises one or more asparagine group at N297 being connected to the rest of the conjugate.



2. The conjugate of any one of the preceding claims, being of Formula (XXX):






wherein each R_A is













wherein d_{13} is 2; and the antibody comprises one or more asparagine group at N297 being connected to the rest of the conjugate.


3. The conjugate of any one of the preceding claims, wherein each R_A is




4. The conjugate of any one of the preceding claims, wherein each R_A is




5. The conjugate of any one of the preceding claims, wherein each R_A is




6. The conjugate of any one of the preceding claims, wherein each R_A is




7. The conjugate of any one of the preceding claims, wherein each R_A is




8. The conjugate of any one of the preceding claims, wherein each R_A is




9. The conjugate of any one of the preceding claims, wherein each R_A is



10. The conjugate of any one of the preceding claims, wherein each R_A is



11. The conjugate of any one of the preceding claims, wherein each R_A is



d_{13} is 2;


ANTIBODY is a NaPi2b antibody comprising: a CDRH1 comprising the amino acid sequence GYTFTGYNIH (SEQ ID NO: 5); a CDRH2 comprising the amino acid sequence AIYPGNGDTSYKQKFRG (SEQ ID NO: 6); a CDRH3 comprising the amino acid sequence GETARATFAY (SEQ ID NO: 7); a CDRL1 comprising the amino acid sequence SASQDIGNFLN (SEQ ID NO: 8); a CDRL2 comprising the amino acid sequence YTSSLYS (SEQ ID NO: 9); and a CDRL3 comprising the amino acid sequence QQYSKLPLT (SEQ ID NO: 10);

the antibody comprises one or more asparagine group at N297 being connected to the rest of the conjugate;

■ is GlcNAc; △ is Fuc; and □ is GalNAc.

13. The conjugate of claim 12, wherein the NaPi2b antibody comprise a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2.

14. A conjugate being of Formula



wherein

d₁₃ is 2;

ANTIBODY is a NaPi2b antibody comprising: a CDRH1 comprising the amino acid sequence GYTFTGYNIH (SEQ ID NO: 5); a CDRH2 comprising the amino acid sequence

AIYPGNGDTSYKQKFRG (SEQ ID NO: 6); a CDRH3 comprising the amino acid sequence GETARATFAY (SEQ ID NO: 7); a CDRL1 comprising the amino acid sequence SASQDIGNFLN (SEQ ID NO: 8); a CDRL2 comprising the amino acid sequence YTSSLYS (SEQ ID NO: 9); and a CDRL3 comprising the amino acid sequence QQYSKLPLT (SEQ ID NO: 10);

the antibody comprises one or more asparagine group at N297 being connected to the rest of the conjugate;

■ is GlcNAc; △ is Fuc; and □ is GalNAc.

15. The conjugate of claim 14, wherein the NaPi2b antibody comprise a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2.

16. A method for preparing an antibody-drug conjugate comprising reacting a modified antibody with a scaffold selected from the scaffolds described in Table B thereby forming a site-specific antibody-drug conjugate, wherein the modified antibody is obtained by contacting a glycoprotein comprising an antibody and core-GlcNAc moiety connected to site N297 of the antibody, with endoglycosidase Endo SH, thereby forming an intermediate antibody comprising a terminal GlcNAc moiety; and contacting the intermediate antibody with 4-AzGalNAc-UDP in the presence of a β -(1,4)-GalNAcT enzyme, thereby forming the modified antibody comprising the modified-GlcNAc moiety; wherein steps (a) and (b) are conducted concurrently.

17. A pharmaceutical composition comprising a conjugate of any one of the preceding claims and a pharmaceutically acceptable carrier.

18. The conjugate of any one of ~~the preceding~~ claims 1-16 for treating a cancer in a subject in need thereof, wherein an effective amount of the conjugate is to be administered to the subject.

19. ~~A method of treating a cancer in a subject in need thereof, comprising administering to the subject~~Use of an effective amount of a conjugate of any one of ~~the preceding~~ claims 1-16, or the pharmaceutical composition of claim 17, in the manufacture of a medicament for treating a cancer in a subject, wherein the medicament is to be administered to the subject.

20. The ~~method-use~~ of claim 19, wherein the cancer is a NaPi2b expressing cancers selected from ovarian cancer, non-small cell lung cancer (NSCLC), endometrial cancer, papillary renal cell cancer, salivary duct cancer, papillary thyroid cancer, clear cell renal cancer, breast cancer, kidney cancer, cervical cancer and cholangiocarcinoma.
21. The ~~method-use~~ of claim 20, wherein the NaPi2b expressing cancer is ovarian cancer, non-small cell lung cancer (NSCLC), endometrial cancer, papillary renal cell cancer, salivary duct cancer, or papillary thyroid cancer.
22. The ~~method-use~~ of claim 20, wherein the NaPi2b expressing cancer is ovarian cancer or non-small cell lung cancer (NSCLC).
23. The ~~method-use~~ of claim 20, wherein the effective amount of the conjugate is ~~administered to the subject at~~ a dose of about between 7 mg/m² to 162 mg/m² on the first day of treatment and every three weeks or four weeks thereafter.
24. The ~~method-use~~ of claim 20, wherein the dose is about 7 mg/m² to about 162 mg/m², (e.g. 7 mg/m², 14 mg/m², 28 mg/m², 56 mg/m², 84 mg/m², 112 mg/m², 135 mg/m² or 162 mg/m²).
25. The ~~method-use~~ of claim 20, wherein the ovarian cancer is platinum resistant ovarian cancer.
26. The ~~method-use~~ of claim 20, wherein the ovarian cancer is high-grade serous ovarian carcinoma.
27. The ~~method-use~~ of claim 20, wherein the ovarian cancer is platinum resistant, high-grade serous ovarian cancer.
28. The ~~method-use~~ of claim 20, wherein the ovarian cancer has received prior single agent chemotherapy.

29. The ~~method-use~~ of claim 20, wherein the subject having ovarian cancer has received no more than 3 lines of prior lines of therapy.
30. The ~~method-use~~ of claim 20, wherein the subject having ovarian cancer has received no more than 3 lines of prior lines of therapy including at least one line of platinum-containing regimen.
31. The ~~method-use~~ of claim 20, wherein the subject having ovarian cancer has received no more than 4 lines of prior lines of therapy with or without at least one line of platinum-containing regimen.
32. The ~~method-use~~ of claim 20, wherein the NSCLC is sub-typed as adenocarcinoma.
33. The ~~method-use~~ of claim 20, wherein the subject has NSCLC and has received prior treatment, with a platinum-based chemotherapy (cisplatin or carboplatin) and a PD-1 or PD-L1 monoclonal antibody.
34. The conjugate of any one of claims 1-16, or the pharmaceutical composition of claim 17, for use in therapy.